Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 10/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106554 | 1.00 | CASR (0.49) | CASRCYP2D6CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL4106570 | 0.88 | CASR (0.54) | CASRCYP2D6CCR5 | |
| SCHEMBL4094857 | 0.87 | CASR (0.51) | CASRCYP2D6CCR5TLR2 | |
| SCHEMBL4094852 | 0.87 | CASR (0.51) | CASRCYP2D6CCR5TLR2 | |
| SCHEMBL4789570 | 0.86 | CASR (0.46) | CASRCYP2D6CA1CA2CA9 | |
| SCHEMBL4789572 | 0.86 | CA1 (0.43) | CASRCYP2D6CA1CA2CA9 | |
| SCHEMBL4110149 | 0.85 | CASR (0.46) | CASRCYP2D6CCR5TLR2 | |
| SCHEMBL4110156 | 0.85 | CASR (0.46) | CASRCYP2D6CCR5TLR2 | |
| SCHEMBL4101477 | 0.85 | CASR (0.53) | CASRCYP2D6CCR5 | |
| SCHEMBL4104683 | 0.84 | CASR (0.50) | CASRCYP2D6CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-7585886-B2 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | ASTELLAS PHARAMA INC. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1882684-A1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062366-A1 | Pyrrolidine derivative or salt thereof | CASR, CYP2R1, PTH1R | CASR 1/4885CYP2D6 341/4885CA1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.